Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

Figure 1

Longitudinal fluctuations of anti-EBNA-1 and anti-VCA IgG in the ten patients with relapsing remitting multiple sclerosis (RRMS) treated with Natalizumab for 21 months in which blood samples were taken at every time point. Serum levels of anti-EBNA-1 and anti-VCA IgG were different among various time points (Friedman test: and , resp.). Serum levels of anti-VCA IgG were more elevated at compared to and (Dunn’s posttest: ) whereas no differences were found comparing each time point for EBNA-1 IgG levels in a post hoc analysis. AU = arbitrary units; EBNA-1 = Epstein-Barr nuclear antigen-1; = baseline; = the 3rd month; = the 6th month; = the 9th month; = the 12th month; = the 15th month; = the 18th month; = the 21st month; VCA = viral capsid antigen. Horizontal bars indicate medians and error bars correspond to interquartile range.

(a)

(b)